Organogenesis Holdings INC Form 4 insider transactions

Chief Commercial Officer Brian Grow exercised options for 958 shares of Class A Common Stock shortly before their expiration date.

Organogenesis Holdings Inc. Director Arthur S Leibowitz purchased 5,000 shares of Class A Common Stock at $2.681 per share.

Organogenesis Holdings Inc.'s Vice President of Strategy, Robert Cavorsi, disposed of 700 shares of Class A Common Stock to cover tax liabilities.

Organogenesis Holdings Inc. Director Glenn H. Nussdorf reported the sale of 200,000 Class A Common Stock shares for approximately $1.027 million.

Glenn H. Nussdorf, a Director and 10% owner of Organogenesis Holdings Inc., sold 300,000 shares of Class A Common Stock over three days in late November 2025.

Organogenesis Holdings Inc. Director and 10% owner Glenn Nussdorf reported recent stock transactions and resolved a Section 16(b) short-swing profit violation.

Organogenesis Holdings Inc.'s Chief Commercial Officer, Brian Grow, executed a pre-planned transaction, exercising stock options and selling a portion of the resulting shares to cover tax obligations.

Organogenesis Holdings Inc.'s Vice President of Strategy, Robert Cavorsi, disposed of 360 shares of Class A Common Stock to cover tax withholding obligations at a price of $4.465 per share.

Lori Freedman, Chief Administrative and Legal Officer of Organogenesis Holdings Inc., has significantly increased her direct beneficial ownership in the company through a series of open market purchases totaling over 250,000 shares.

Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., disposed of shares to cover tax obligations arising from vested stock.

Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis Holdings Inc. (ORGO) at an average price of $5.1014 on March 4, 2025.

Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., reports a transaction involving Class A Common Stock on March 1, 2025.

Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., was granted stock options and restricted stock units (RSUs) on February 19, 2025.

Chief Operating Officer Patrick Bilbo reports the acquisition of restricted stock units and stock options in Organogenesis Holdings Inc.

Antonio S. Montecalvo, Vice President of Health Policy at Organogenesis Holdings Inc., received stock options and restricted stock units (RSUs) on February 19, 2025, according to a Form 4 filing.

Chief Commercial Officer Brian Grow of Organogenesis Holdings Inc. reports the acquisition of restricted stock units and stock options.

Lori Freedman, Chief Admin. and Legal Officer of Organogenesis Holdings Inc., reports the acquisition of restricted stock units and stock options.

Chief Financial Officer David Francisco of Organogenesis Holdings Inc. reports the acquisition of restricted stock units and stock options.

Director Quintero Gilberto reports acquisition and disposal of Organogenesis Holdings Inc. Class A Common Stock and Restricted Stock Units.

Director Garrett Lustig reports receiving a grant of restricted stock units and disposing of Class A Common Stock.

Director Arthur S. Leibowitz of Organogenesis Holdings Inc. reports the acquisition of restricted stock units (RSUs) under the company's 2018 Equity Incentive Plan.

Director Michele Ilene Korfin of Organogenesis Holdings Inc. was granted 49,575 restricted stock units (RSUs) on February 19, 2025, vesting fully on February 15, 2026.

Gary S. Gillheeney, President and CEO of Organogenesis Holdings Inc., received stock options and restricted stock units (RSUs) on February 19, 2025.

Director Jon L Giacomin received a grant of restricted stock units from Organogenesis Holdings, vesting in February 2026.

Director Duraibabu Prathyusha reports receiving a grant of restricted stock units and changes in beneficial ownership of Organogenesis Holdings Inc. stock.

Director Michael Joseph Driscoll reports acquisition of Organogenesis Holdings Inc. Class A Common Stock and grant of restricted stock units.

Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., disposed of shares to cover tax obligations.

Antonio S. Montecalvo, Vice President of Health Policy at Organogenesis Holdings Inc., reports the disposal of Class A Common Stock to cover tax obligations.

Gary S. Gillheeney, President and CEO of Organogenesis Holdings Inc., reports the disposition of Class A Common Stock to cover tax obligations.

Brian Grow, Chief Commercial Officer of Organogenesis Holdings Inc., disposed of shares to cover tax obligations arising from vesting of restricted stock units.